In vitro studies have demonstrated that in human breast cancer cells AhR, cyclin D1 and cyclin dependent kinase 4 (CDK4) interact within the cell cycle and the interaction was disrupted upon TCDD treatment. The gene discussed is CDK4; the disease is breast cancer.